EdgeMarket › What Samsara Biocapital, Llc reported owning
What Samsara Biocapital, Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.0BPositions
22Quarter
2026-03-31Shown below
22largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| SRRK Scholar Rock Holding Corp | 339.1M | 32.9% | 6.9M | 56.50 | +64.2% |
| MLYS Mineralys Therapeutics, Inc. | 159.0M | 15.5% | 5.9M | 25.65 | +65.7% |
| ALMS ALUMIS INC. | 139.8M | 13.6% | 6.3M | 24.17 | +448.1% |
| SEPN Septerna, Inc. | 75.7M | 7.4% | 3.1M | 40.00 | +260.7% |
| KLRS Kalaris Therapeutics, Inc. | 74.7M | 7.3% | 12.9M | 4.15 | +61.5% |
| SGP SpyGlass Pharma, Inc. | 54.7M | 5.3% | 2.1M | 26.51 | — |
| NGNE Neurogene Inc. | 34.6M | 3.4% | 1.7M | 38.63 | +97.0% |
| IVA Inventiva S.A. | 28.8M | 2.8% | 5.2M | 4.68 | +2.2% |
| STRO SUTRO BIOPHARMA, INC. | 26.5M | 2.6% | 1.1M | 21.04 | +143.4% |
| JBIO Jade Biosciences, Inc. | 13.6M | 1.3% | 968.8K | 21.34 | +211.5% |
| VTVT vTv Therapeutics Inc. | 11.8M | 1.2% | 298.5K | 33.26 | +121.7% |
| AQST Aquestive Therapeutics, Inc. | 10.4M | 1.0% | 2.5M | 4.66 | +20.1% |
| XFOR X4 Pharmaceuticals, Inc | 7.6M | 0.7% | 1.8M | 4.04 | +44.3% |
| NKTX Nkarta, Inc. | 7.4M | 0.7% | 3.5M | 2.66 | +17.7% |
| unmapped CUSIP 03940C100 | 7.0M | 0.7% | 60.9K | — | — |
| UPB Upstream Bio, Inc. | 6.6M | 0.6% | 736.0K | 6.97 | -57.4% |
| ABVX Abivax S.A. | 6.3M | 0.6% | 56.6K | 114.95 | +59.9% |
| AGMB Agomab Therapeutics NV | 6.3M | 0.6% | 600.0K | 13.25 | — |
| RANI Rani Therapeutics Holdings, Inc. | 6.2M | 0.6% | 8.5M | 0.88 | +66.2% |
| CHRS Coherus Oncology, Inc. | 5.8M | 0.6% | 3.4M | 1.42 | +32.7% |
| PVLA PALVELLA THERAPEUTICS, INC. | 4.8M | 0.5% | 38.4K | 142.04 | +181.6% |
| GOSS Gossamer Bio, Inc. | 2.4M | 0.2% | 7.2M | 0.15 | -92.1% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →